Enifrav (Warfarin Sodium)

Enifrav is indicated for several thromboembolic disorders where anticoagulation is required.

• Prevention and treatment of venous thromboembolism (deep‑vein thrombosis and pulmonary embolism).
• Prophylaxis of stroke and systemic embolism in patients with non‑valvular atrial fibrillation.
• Prevention of thromboembolic complications in individuals with mechanical heart valve prostheses.
• Long‑term anticoagulation in patients with recurrent clotting disorders as determined by a physician.

Side effects of Enifrav vary in frequency and severity; they are categorized as common and serious.

Common

• Minor bruising or bleeding from gums, nose, or cuts.
• Small amounts of blood in urine or stool.
• Nausea, abdominal discomfort, or loss of appetite.
• Skin rash or mild itching.
• Dizziness or light‑headedness.

Serious

• Significant bleeding such as gastrointestinal hemorrhage or intracranial bleed.
• Severe allergic reaction with swelling of the face, lips, or throat.
• Unexplained drop in hemoglobin or hematocrit levels.
• Purple or black discoloration of the skin (purpura).
• Rapid drop in blood pressure (hypotension) due to bleeding.

Before initiating Enifrav, clinicians evaluate several precautionary factors to minimize bleeding risk and ensure safe use.

• Baseline assessment of INR or PT/INR values and regular monitoring during therapy.
• Evaluation of liver function, as impaired hepatic metabolism can increase drug exposure.
• Review of patient history for prior hemorrhagic events, gastrointestinal ulcers, or intracranial bleeding.
• Consideration of age, renal function, and concomitant use of antiplatelet agents.
• Education on signs of bleeding and instructions to avoid activities that may cause trauma.
• Pregnancy and lactation status should be assessed, as warfarin crosses the placenta.

Enifrav interacts with many medications; some combinations should be avoided, while others require careful dose adjustment and monitoring.

Avoid

• Strong CYP2C9 inhibitors such as fluconazole, amiodarone, and certain macrolide antibiotics.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) and aspirin that increase bleeding risk.
• Antiplatelet agents like clopidogrel or ticagrelor without close supervision.

Use with caution

• Vitamin K‑rich foods or supplements that may reduce anticoagulant effect.
• Other anticoagulants (e.g., heparin, direct oral anticoagulants) when transitioning therapy.
• Herbal products such as ginkgo biloba, garlic, or St. John’s wort that can affect coagulation.